The global Nucleic Acid Testing Market is expected to reach US$ 3.7 billion by 2023. The market is expected to reach US$ 7.2 billion by 2033, growing at a strong 6.8% CAGR.

Major factors influencing the growth of the nucleic acid amplification testing market include the rising incidence of infectious diseases, cancers, and other diseases, improvements in healthcare infrastructure, and increased awareness of nucleic acid testing techniques for screening pathogenic bacteria and viruses in patients' blood, tissue, and urine.

Increasing R&D activity in the area to innovate diagnostic processes is estimated to boost nucleic acid testing market growth over the forecast period.

Market players have created new product offerings including isothermal nucleic acid amplification tests to meet the rising need for fast testing, nucleic acid point-of-care testing, and molecular nucleic acid testing.

Request a Sample of this Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-1106

The Stumbling Blocks of the Market

The necessity for dedicated infrastructure, a shortage of qualified technical experience, and high sensitivity are all issues that could stymie expansion in the global nucleic acid testing market.

The high costs, a shortage of experienced specialists, and safety concerns are projected to stymie market expansion over the projection period.

Regional Outlook

North America and Europe are the two major nucleic acid amplification testing market at the moment, and they are likely to account for a significant percentage of the market during the forecast period as well.

North America

Due to the high prevalence of chronic diseases and the presence of an established research and healthcare infrastructure, North America accounted for the greatest market share. Similarly, the increased emphasis on point-of-care diagnostic procedures, and the region's extensive disease prevention programmes fuel demand for nucleic acid testing.

Increased investments in diagnostics and research, as well as an increase in the prevalence of infectious disorders, are likely to boost the nucleic acid testing market in North America over the forecast period.

Asia Pacific

Asia Pacific is predicted to exhibit a considerably higher CAGR, owing to factors such as increased awareness of the nucleic acid test combined with a transfer of research institutes and contract research companies from developed western countries to emerging countries in Asia Pacific.

Key Takeaways

By 2033, the Indian nucleic acid amplification testing market is estimated to reach US$ 341.3 million.
By 2033, it is estimated that the Chinese market for nucleic acid testing to reach US$ 659.1 million.
The Japanese market for nucleic acid testing is expected to generate US$ 525.6 million in revenue by 2033.
During the projection year, the US market may grow at a CAGR of 6.8%.
The kits product type is expected to increase at a CAGR of 6.4% during the projected period.
The CAGR for the UK market might be 6.7% between 2023 and 2033.
The Japanese market is expected to increase at a CAGR of 6.3% over the forecast period.
The Indian nucleic acid testing market is expected to develop at a CAGR of 10.6% between 2023 and 2033.
The Chinese market for nucleic acid testing is expected to grow at a CAGR of 7% between 2023 and 2033.
The UK market for nucleic acid testing is estimated to produce US$ 267.5 Mn in sales by 2033.
The US market is estimated to reach US$ 2.0 Bn by 2033.
Infectious Diseases may grow at a CAGR of 7.1% in the indication category during the predicted year.

Nucleic Acid Testing Market Competitive Landscape

Due to strategic initiatives taken by emerging and significant companies, the nucleic acid testing market is extremely competitive. Several new types of nucleic acid testing have been introduced in recent years.

Agilent Technologies, Danaher Corporation, Abbott Laboratories, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Beckman Coulter, Inc., Illumina, Inc., Siemens AG, Hologic Inc., bioMérieux SA, Novartis AG, F. Hoffmann-La Roche Ltd., Sequenom, Tecan Trading AG., and others are among the main players in the global market.

Recent Development

Launch

September 2022, My lab Discovery Solutions debuted their Patho Detect HPV Identification PCR Test for the detection of human papillomavirus (HPV) in high-risk patients.

Upgrade

Abingdon Health announced a new version of the successful NALFIA fast test in January 2019 for the detection of DIG/Biotin and/or FITC (Or FAM)/biotin-labeled analytes.

Introduction

In September 2018, researchers at the National University of Singapore created a portable platform for a point-of-care nucleic acid test that can be used to diagnose a variety of diseases. "enVision" is the name of the device (enzyme-assisted nanocomplexes for visual identification of nucleic acids)

Key Segments

By Product Type:

Nucleic Acid Test Kits
Transcription-Mediated Amplification (TMA)
Polymerase Chain Reaction (PCR)
Ligase Chain Reaction (LCR)
Whole Genome Sequencing
Consumables

By Indication:

Infectious diseases
Cancer
Forensic Testing
Others

By End-user:

Hospitals
Pathology laboratories
Research Institutes
Clinics

By Region:

North America
Latin America
Western Europe
Eastern Europe
APECJ
China
Japan
MEA